<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Variations Improper activation and inappropriate expression of fibroblast growth factor receptors (<italic>FGFRs</italic>) in cancer suggests that they can act as therapeutic targets. Fibroblast growth factor receptor inhibitors are currently employed in clinical trials of different cancers. Regarding the essence and the importance of the personalized medicine, mainly mirrored by remarkable inter-individual variations in different populations, we aimed to perform a pilot study to address <italic>FGFR1</italic> and <italic>FGFR3</italic> expression levels and their correlation with the clinicopathological features in Iranian patients with bladder cancer (BC). Paired tumor and adjacent non tumor tissue samples along with their clinico-pathological parameters were obtained from 50 cases diagnosed with BC in different stages and grades. The mRNA expressions of <italic>FGFR1</italic> and <italic>FGFR3</italic> in tissue samples were determined by real-time polymerase chain reaction (real-time PCR). The expression levels of <italic>FGFR3</italic> were significantly higher in tumor tissues when compared to adjacent normal tissues (<italic>p</italic> = 0.007), regardless of the stages and grades of the tumor. Over expression was associated with cigarette smoking (<italic>p</italic> = 0.037) and family history for cancer (<italic>p</italic> = 0.004). Decreased expression of <italic>FGFR1</italic> was observed, remarkably evident in high-grade tumors (<italic>p</italic> = 0.047), while over expression was detected in low-grade samples. This pilot study clearly suggests that in Iranian BC patients <italic>FGFR1</italic> and <italic>FGFR3</italic> expression patterns are different, and also highly distinctive with regard to the tumor’s stage and grade. Such particular expression patterns may indicate their special values to be employed for interventional studies aiming targeted therapy. Further studies with a larger sample size are needed to validate our results.</p></abstract>

Variations Improper activation and inappropriate expression of fibroblast growth factor receptors (FGFRs) in cancer suggests that they can act as therapeutic targets. Fibroblast growth factor receptor inhibitors are currently employed in clinical trials of different cancers. Regarding the essence and the importance of the personalized medicine, mainly mirrored by remarkable inter-individual variations in different populations, we aimed to perform a pilot study to address FGFR1 and FGFR3 expression levels and their correlation with the clinicopathological features in Iranian patients with bladder cancer (BC). Paired tumor and adjacent non tumor tissue samples along with their clinico-pathological parameters were obtained from 50 cases diagnosed with BC in different stages and grades. The mRNA expressions of FGFR1 and FGFR3 in tissue samples were determined by real-time polymerase chain reaction (real-time PCR). The expression levels of FGFR3 were significantly higher in tumor tissues when compared to adjacent normal tissues (p = 0.007), regardless of the stages and grades of the tumor. Over expression was associated with cigarette smoking (p = 0.037) and family history for cancer (p = 0.004). Decreased expression of FGFR1 was observed, remarkably evident in high-grade tumors (p = 0.047), while over expression was detected in low-grade samples. This pilot study clearly suggests that in Iranian BC patients FGFR1 and FGFR3 expression patterns are different, and also highly distinctive with regard to the tumor’s stage and grade. Such particular expression patterns may indicate their special values to be employed for interventional studies aiming targeted therapy. Further studies with a larger sample size are needed to validate our results.

Differential expression of FGFRs signaling pathway components in bladder cancer: A step toward personalized medicine

Department of Pathobiology, School of Public Health

Department of Medical Immunology and Genetics, Faculty of Medicine

Balkan Journal of Medical Genetics

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Variations Improper activation and inappropriate expression of fibroblast growth factor receptors (FGFRs) in cancer suggests that they can act as therapeutic...

Primers	Sequences (5′<3′)	Amplicon Size
FGFR1-F	GAA GAC TGC TGG AGT TAA TAC C	159
FGFR1-R	TCT TCC AGG GCT TCC AGA AC	159

FGFR3-F	CCA CTG TCT GGG TCA AGG AT	180
FGFR3-R	AGG ATG GAG CGT CTG TCA C	180

GAPDH-F	ATC CTG GGC TAC ACT GAG C	159
GAPDH-R	CAC CAC CCT GTT GCT GTA G	159

Clinicopathological Parameters	n	%
Age (years):
≤66	26	52.0
>66	24	48.0

Sex:
males	43	86.0
females	7	14.0

Stage:
I	16	32.0
II	20	40.0
III	10	20.0
IV	4	8.0

Grade:
low	14	28.0
high	36	72.0

Tumor type:
non invasive muscle	15	30.0
muscle invasive	35	70.0

Family history:
bladder cancer	8	16.0
other cancer	6	12.0
no cancer	36	72.0

Smoker:
≤10	2	4.0
>10	32	64.0
non smoker	16	32.0

Occupational exposure	27	54.0

Relative Expression	Variable(s)	Undersized Coefficients B	Standard Error B	t-Test	p Value
FGFR1	no significant variable

FGFR3	(constant) family history of BC cigarette smoking	–28.908	11.031	–2.621	0.021
		14.266	4.125	3.458	0.004
		11.568	4.968	2.329	0.037

Differential expression of FGFRs signaling pathway components in bladder cancer: A step toward personalized medicine

Article Category: Original Article

Pubblicato online: 29 dic 2017

Pagine: 75 - 81

DOI: https://doi.org/10.1515/bjmg-2017-0026

Parole chiave
Bladder cancer (BC), FGFR signaling, Targeted therapy

© 2017 Ousati Ashtiani Z, Tavakkoly-Bazzaz J, Salami SA, Pourmand MR, Mansouri F, Mashahdi R, Pourmand G, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Figure 2

List of primer sets for real-time polymerase chain reaction.

Clinicopathological characteristics of the study subjects.

Multivariate linear regression analysis of FGFR1 and FGFR3 expressions with clinicopathological variables.

Differential expression of FGFRs signaling pathway components in bladder cancer: A step toward personalized medicine

Article Category: Original Article

Pubblicato online: 29 dic 2017

Pagine: 75 - 81

DOI: https://doi.org/10.1515/bjmg-2017-0026

Parole chiaveBladder cancer (BC), FGFR signaling, Targeted therapy

© 2017 Ousati Ashtiani Z, Tavakkoly-Bazzaz J, Salami SA, Pourmand MR, Mansouri F, Mashahdi R, Pourmand G, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Figure 2

List of primer sets for real-time polymerase chain reaction.

Clinicopathological characteristics of the study subjects.

Multivariate linear regression analysis of FGFR1 and FGFR3 expressions with clinicopathological variables.

Parole chiave
Bladder cancer (BC), FGFR signaling, Targeted therapy